Highlights
1. Pramipexole augmentation significantly reduces depressive symptoms at 12 weeks in patients with treatment-resistant unipolar depression compared to placebo.
2. The trial employed a robust multicentre, double-blind, placebo-controlled randomised design involving 150 participants across nine NHS Trusts.
3. While effective, pramipexole was associated with some adverse effects, including impulse control difficulties and symptoms of mania.
4. Findings support pramipexole as a promising augmentation strategy, warranting further head-to-head comparisons with established treatments.
